Grifols SA - Company Profile
Powered by 
All the sales intelligence you need on Grifols SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Grifols SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Grifols SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Grifols SA (Grifols) develops, produces, and markets plasma-derived medicines and transfusion medicines. The company is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering from rare, chronic and life-threatening infections.The company's major products include essential plasma-derived medicines for treating conditions across various therapeutic areas such as neurology, immunology, hepatology, hematology, intensive care, pulmonology, and other infectious diseases. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
Parque Empresarial Can Sant Joan, Avinguda De La Generalitat, 152-158, Sant Cugat Del Valles, Barcelona , 08174
Website
www.grifols.com
Telephone
34 935 712200
No of Employees
23,822
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRF (MCE)
Revenue (2024)
$8.5B
4.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
156.2%
(2024 vs 2023)
Market Cap*
$6.3B
Net Profit Margin (2024)
XYZ
145.0%
(2024 vs 2023)
* As of and is in US$
Grifols SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Bioscience: | Testing Services | Albutein |
| Plasma Derivative Products | Plasma Testing | Alphanate |
| Diagnostic: | Clinical Diagnostics | Anbinex |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In June, the company unveiled Evanzys IH, a next-generation automated system. |
| 2026 | Contracts/Agreements | In March, the company renewed its partnership with Ace Alzheimer Center Barcelona. |
| 2025 | Regulatory Approval | In November, the company secured approval from the Paul-Ehrlich-Institut for its fibrinogen concentrate to treat patients with congenital and acquired fibrinogen deficiency. |
Competitor Comparison
| Key Parameters | Grifols SA | Sanofi | Takeda Pharmaceutical Co Ltd | Vertex Pharmaceuticals Inc | Omnicell Inc |
|---|---|---|---|---|---|
| Headquarters | Spain | France | Japan | United States of America | United States of America |
| City | Sant Cugat Del Valles | Paris | Chuo-Ku | Boston | Fort Worth |
| State/Province | Barcelona | Ile-de-France | Tokyo | Massachusetts | Texas |
| No. of Employees | 23,822 | 76,493 | 47,029 | 6,400 | 3,580 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Victor Grifols Roura | Chairman | Executive Board | 2023 | - |
| Raimon Grifols Roura | Vice Chairman; Director | Executive Board | 2025 | 61 |
| Nacho Abia | Director; Chief Executive Officer | Executive Board | - | 57 |
| Rahul Srinivasan | Chief Financial Officer | Senior Management | 2024 | 48 |
| Camille Alpi | Chief Human Resources Officer; Chief Talent Officer | Senior Management | 2024 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer